News & Updates
Showing Pharmacy articles
Showing
Fezolinetant eases symptoms in menopausal women unfit for hormone therapy
Use of fezolinetant demonstrates efficacy and good tolerability in the treatment of moderate-to-severe vasomotor symptoms associated with menopause in women who are deemed unsuitable for hormone therapy, reports a study.
Pooled analysis ASSUREs seladelpar role in PBC
Results of the phase III ASSURE study support seladelpar – a novel first-in-class delpar (selective peroxisome proliferator-activated receptor delta agonist) – for the treatment of primary biliary cholangitis (PBC).
Why not metformin for long COVID in non-diabetics?
Metformin prescribed within a week of SARS-CoV-2 infection was associated with a 53-percent reduction in long COVID or death over 6 months in patients without diabetes or prediabetes, as shown in a simulation study presented at IDWeek 2024.
Palbociclib vs abemaciclib: How to choose the right treatment for breast cancer patients
A study suggests that in choosing CDK4/6 inhibitors (palbociclib and abemaciclib) for patients with hormone receptor-positive, HER2-negative metastatic/recurrent breast cancer, considerations must be made based on the tolerability and manageability of adverse events (AEs).